A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Summary

A study to evaluate the safety, pharmacokinetics and anti-tumor activity of RO7300490 as a single agent or in combination with atezolizumab. The study will consist of 3 parts: \[Part 1\] Dose-Escalation of RO7300490 as a single agent; \[Part 2\] Dose-Escalation of RO7300490 in combination with atezolizumab and \[Part 3\] Dose-Expansion of RO7300490 in combination with atezolizumab in selected cancer types.

Timeline

Start

2021-05-18

Primary completion

2024-01-18

Completion

2024-01-18

Publications

• Melero I, Reis B, Rusterholz C, Epp A, Kratochwil NA, Wu C, Hettich M, Kazantzidis G, Rieder N, Schwalie PC, Badillo S, Kumpesa N, Thommen A, Vugts DJ, Moreno V, Lostes Bardaji J, Alvarez EC, de Andrea CE, Spanggaard I, Lee DH, Spicer J, Thistlethwaite F, Oh DY, Hollebecque A, Cirovic O, Symeonides SN. Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. Nat Cancer. 2026 May;7(5):840-856. doi: 10.1038/s43018-026-01157-8. Epub 2026 May 1.

Drugs

Indications